Compare Abeona Therapeutics Inc (ABEO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs M&T Bank Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while M&T Bank Corporation trades at $233.71 (market cap $35.11B). The key difference: M&T Bank Corporation is far larger — about 94× Abeona Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.5% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MTB | |
|---|---|---|
Market Cap | $373.32M | $35.11B |
Sector | Health | Financials |
52-Week High | $7.23 | $241.95 |
52-Week Low | $4.17 | $178.63 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MTB trades at $239.75, up 0.36% today, near the consensus price target of $241.56. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $9.63B in 2025, with a strong net income margin of 29.59%. Recent news highlights upcoming Q2 2026 earnings and strategic leadership appointments, reinforcing operational focus.
The outlook is cautiously positive, supported by solid fundamentals and analyst consensus, but risks include elevated investing cash outflows and sensitivity to interest rate changes. The stock presents a value opportunity with a reasonable P/E of 13.47, though investor sentiment remains mixed ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
